Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 22, Issue 12_Supplement
1 December 2023
Issue Cover
ISSN 1535-7163
EISSN 1538-8514
In this Issue
Search within issue

Abstracts: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 11-15, 2023; Boston, MA

Angiogenesis and Antiangiogenesis agents

Animal Models

Apoptosis, Necrosis, and Autophagy

Bioinformatics

Biomarkers

Cancer Stem Cells

Cell Cycle Regulators

Cellular Responses to Therapy

Challenges and Prospects in the Analysis of Spatial and Single Cell Biology

Chemistry

Clinical Trials

Differentiation

DNA Repair and Modulation

Drug Delivery

Drug Design

Drug Metabolism, Transport, and Biodistribution

Drug Resistance and Modifiers

Drug Screening

EGFR/Her2

Emerging Role of Therapeutic Vaccines and mRNA in Cancer

Epigenetic Regulation of Tumor Immunity

Epigenetic Targets

Gene Therapies

Genomics, Proteomics and Target Discovery

Glyco-immunology in Cancer Drug Development

Hormonal Agents and Therapy

Imaging

Immune Checkpoints

Immune Mechanisms Invoked by Radiation Therapy

Immune Modulators

Immune Monitoring/Clinical Correlates

Immune Response to Therapies

In Vitro and In Vivo Models for Targets

MAPK Pathways

Metabolism

Metastasis and Invasion

Molecular Classification of Tumors

Monoclonal Antibodies

mTOR/PI3-Kinase

Natural Products

New Molecular Targets

Next-Generation Cytokine Engineering for Cancer

Novel Assay Technology

Other Topics

Patient-Derived Models to Accelerate Drug Discovery

Pediatric-Early Drug Development

Pharmacogenetics, Pharmacogenomics, and Therapeutic Response

Pharmacokinetics and Pharmacodynamics

Protein-Protein Interaction

Radiotherapeutics

RNA and RNA-based Technologies and Therapies

Signal Transduction Modulators

Target Identification and Validation

Targeting Stromal Cells in Cancer Immunotherapy

T-cell Engaging Bispecific Antibodies in Solid Tumors

The Future of Tumor Agnostic Drug Development

The Journey of Antibody Drug Conjugate Development

Therapeutic Agents: Biological

Therapeutic Agents: Other Topics

Therapeutic Agents: Small-Molecule Kinase Inhibitors

Topoisomerase Inhibitors

Tumor Immunology Targets

Tumor Microenvironment

Tumor Suppressors

All Issues

Advertisement

Breaking
Daratumumab Can Prevent Progression of Myeloma Precursor
Blinatumomab + Chemo Best for B-cell ALL in Kids
Bacterium-Derived Therapy Effective for Bladder Cancer
View more recent articles
Latest News
Genetic Pattern in Prenatal DNA Tests Linked to Maternal Cancers
Prevention and Screening Preclude 80% of Cancer Deaths
Tumors Leverage Liver Metabolism to Fuel Growth With Fructose
View more recent articles
Research Watch
The Liver X Receptor Axis Balances Intestinal Regeneration and Tumorigenesis
Oncolytic Virotherapy Plus Nivolumab Is Safe in Muscle-Invasive Bladder Cancer
Specialized Fibroblasts Shape T-Cell Environments in Lung Cancer
View more recent articles

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.

  • Online ISSN 1538-8514
  • Print ISSN 1535-7163

AACR Journals

 

 

  • Copyright © 2023 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept